Hengsai Bio Secures Tens of Millions in A+ Funding Round to Advance DC Vaccine Pipeline and R&D Facilities

According to Hengsai Biotech's official WeChat, following the completion of a hundred-million-level financing in November 2023, Hengsai Biotech has recently secured another multi-million yuan A+ round of financing. The funds will be used to advance the expansion of the product pipeline and clinical applications, as well as the construction of the Zhongshan R&D center and pilot production facility. This round of financing was jointly invested by CUIHENG GROUP, Zhongshan Xiwan Investment Holding Development Co., Ltd., Zhongshan Venture Capital Co., Ltd., and Chengming Capital.